Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 2964-2966

  Powis, Garth ^a   Ihle, Nathan ^a   Kirkpatrick, D Lynn ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; BEC 235; BEVACIZUMAB; IC 486068; IMIDAZOPYRIDINE DERIVATIVE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIOGLITAZONE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PX 316; PX 866; RAPAMYCIN; SF 1126; UNCLASSIFIED DRUG; WORTMANNIN; ZSTK 474;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; DRUG INHIBITION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 33744816775     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0617     Document Type: Short Survey

References (26)

1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
2. Cheng JQ, Linsley CW, Cheng GZ, Yang, Nicosia SV. The Akt/PKB pathway: molecular targets for cancer drug discovery. Oncogene 2005;24:7482-92.
3. Powis G, Bonjouklian R, Berggren M, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54: 2419-23.
4. Davies SP, Reddy H, Caivano N, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351: 95-105.
5. Stam JC, Geerts WJ, Versteeg HH, Verkleij AJ, van Bergen EN, Henegouwen PM. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. J Biol Chem 2001;276:25176-83.
6. Ohta T, Ohmichi M, Hayasaka T, et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006;210:2005-9.
7. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
8. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:1-10.
9. Chen E, Tannock IF. Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA 2004;292:2150-1.
10. Ihle N, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3- kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4: 1349-57.
11. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4:977-86.
12. Kondapaka SB, Singh SS, Dasmahepatra GP, Sausville EA, Roy KK. Perifosine a novel alkyphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103.
13. Meuillet EJ, Ihle N, Baker AF, et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004;14:513-27.
14. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
15. 473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res 2004;10:7192-8.
16. Powis G, Ihle NT, Kirkpatrick L. Potentiation of the antitumor activity of the PI3K inhibitor PX-866 by the PPAR-γ agonist pioglitazone associated with a reversal of hyperglycemia and a decreased glucose tolerance [abstract C130]. Philadelphia (PA): AACR-NCI-EORTC International Conference: 2005.
17. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110β, γ and δ isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006;103:1289-94.
18. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004;32:393-6.
19. Geng L, Tan T, Himmelfarb E, et al. A specific antagonist of the p110 catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res 2004;64:4893-9.
20. http://nmok.net. Targeted Therapeutics in Oncology. February 2005.
21. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8.
22. Lin X, Bohle AS, Dohrmann P, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001;386:293-301.
23. Choe G, Horvath S, CloughesyTF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63: 2742-6.
24. Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol. In press 2006.
25. Papadimitrakopoulou V, Angelaki S, Lnu S, Brown E, Ayers G. The cytotoxic effects of 17-AAG, an inhibitor of Hsp90 are enhanced by combination with the PI-3-kinase inhibitor LY 294002 in non-small cell lung cancer (NSCLC) cell lines. Eur J Cancer Suppl 2004;2: 94-7.
26. Brouckaert P, Huyghe L, Goethais A, Hostens J, Van den Hemel M. Combination with PI3 kinase inhibitors allows drastic dose reduction of tumor necrosis factor. Eur J Cancer Suppl 2004;2:167-73.